Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 3,502 INR
Change Today -20.30 / -0.58%
Volume 7.8K
GLXO On Other Exchanges
Natl India
As of 3:12 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline pharmaceutic (GLXO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/15 - 3,574
52 Week Low
08/12/14 - 2,400
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

glaxosmithkline pharmaceutic (GLXO) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline pharmaceutic (GLXO) Details

GlaxoSmithKline Pharmaceuticals Limited operates as research-based healthcare and pharmaceutical company worldwide. It manufactures, distributes, and trades pharmaceuticals for a range of therapeutic areas, including analgesic, anti-infective, anti-inflammatory, anti-parasitic, cardiovascular, dermatology, diabetes, endocrine, gastrointestinal, gynecology, immunosupressants, nutritional, respiratory, CNS, and oncology diseases. The company also offers vaccines for the prevention of various diseases comprising hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia, and others. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is based in Mumbai, India.

Founded in 1924

glaxosmithkline pharmaceutic (GLXO) Top Compensated Officers

Executive Director and Member of Investors/Sh...
Total Annual Compensation: 26.1M
Executive Director of Technical and Executive...
Total Annual Compensation: 7.0M
Executive Director of Human Resources and Exe...
Total Annual Compensation: 7.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline pharmaceutic (GLXO) Key Developments

GlaxoSmithkline Pharmaceuticals Limited Approves Amendment to Articles of Association

GlaxoSmithkline Pharmaceuticals Limited announced that at the annual general meeting held on July 31, 2015, it has approved amendment to articles of association of the company.

GlaxoSmithkline Pharmaceuticals Limited Reports Unaudited Standalone Financial Results for the First Quarter Ended June 30, 2015

GlaxoSmithkline Pharmaceuticals Limited reported unaudited standalone financial results for the first quarter ended June 30, 2015. For the quarter, the company reported profit from operations before other income & exceptional items of INR 1,051 million against INR 1,092 million for the same period of last year. Profit from ordinary activities before tax was INR 1,426 million against INR 1,490 million for the same period of last year. Net profit for the period was INR 933 million or INR 11 per basic and diluted share against INR 983 million or INR 11.6 per basic and diluted share for the same period of last year. Total income from operations (net) were INR 6,283 million against INR 6,620.5 million for the same period of last year.

Glaxosmithkline Pharmaceuticals Proposes Amendment to Articles of Association

GlaxoSmithkline Pharmaceuticals Limited at the annual general meeting to be held on July 31, 2015 will consider amendment to articles of association.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLXO:IN 3,502.00 INR -20.30

GLXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLXO.
View Industry Companies

Industry Analysis


Industry Average

Valuation GLXO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PHARMACEUTIC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at